Dan Liu

Dan Liu

Auto-generated profile, based on publicly available information

Dan Liu

Department of Pharmacy the First Affiliated Hospital of Army Medical University (Third Military Medical University) Chongqing China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
XLXingxing Li
Xingxing Li
LZLin Zhang
Lin Zhang
SHSang Hu
Sang Hu
DLDan Liu
Dan Liu
BHBin Hu
Bin Hu
JHJing Hu
Jing Hu

7 April 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
DLDan Liu
Dan Liu
XLXingxing Li
Xingxing Li
LZLin Zhang
Lin Zhang
BHBin Hu
Bin Hu
SHSang Hu
Sang Hu
JHJing Hu
Jing Hu
Osteoarthritis (OA) is one of the common degenerative joint diseases in clinic. It mainly damages articular cartilage, causing pain, swelling and stiffness around joints, and is the main cause of disability of the elderly. Due to the unclear pathogenesis of osteoarthritis and the poor self-healing ability of articular cartilage, the treatment options for this disease are limited. At present, NSAIDs, Glucocorticoid and Duloxetine are the most commonly used treatment choice for osteoarthritis. Although it is somewhat effective, the adverse reactions are frequent and serious. The development of safer and more effective anti-osteoarthritis drugs is essential and urgent. This review summarizes recent advances in the pharmacological treatment of OA, focusing on small molecule inhibitors targeting cartilage remodeling in osteoarthritis as well as the research idea of reducing adverse effects by optimizing the dosage form of traditional drugs for the treatment of osteoarthritis. It should provide a reference for exploration of new potential treatment options.